Endometrioid adenocarcinoma of the prostate: A clinicopathologic and immunohistochemical study

Abstract

On retrospective review of the tumor registry files between 1979 and 1992 at the North Iowa Medical Center, six cases of endometrioid adenocarcinoma of the prostate were identified among 1582 cases of prostatic carcinoma. Along with long-term clinicopathologic follow-up, immunohistochemical studies of the prostatic tumor tissues were performed. All six cases of endometrioid carcinoma, together with control cases of benign prostatic hypertrophy (BPH) and ordinary adenocarcinoma of the prostate had unequivocal diffuse positive staining for PSA and similar reactivity to ER-D5 and PS2. Thus, endometrioid carcinoma is most likely derived from the prostate or prostatic urethral duct rather than the utricle. However, due to its unusual initial clinical manifestations, biological behavior, and distinctive histomorphology, the term "endometrioid adenocarcinoma of the prostate" is worth preserving.

Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate

“…25 In a small series, ductal adenocarcinomas displayed more frequent cytokeratin 20 expression. 16 Immunohistochemical staining for other proteins, including estrogen receptor, androgen receptor, p53, bcl-2, and CEA, has been performed in a few ductal adenocarcinoma cases, 7,14,18,19,30 but it is not established whether there is a difference in expression compared with acinar adenocarcinoma. Genes identified as exhibiting a greater than twofold change in ductal versus acinar adenocarcinoma are potential candidates for further study in attempts to explain the different histopathological features and disparate clinical behavior of ductal adenocarcinoma of the prostate.…”

“…Limited scale data do exist on comparative protein expression in ductal versus acinar adenocarcinoma, 7,12,[14][15][16][17][18][19][20][21][22][23][24][25] but comparative global gene expression profiling has not been performed. The aim of this study was to examine the gene expression profiles of ductal versus acinar adenocarcinoma to assess the molecular relatedness of ductal and acinar adenocarcinomas and to identify potential molecular differences that may explain the different histopathological features and disparate clinical behavior of ductal adenocarcinoma of the prostate.…”

Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features

“…29 Lee et al reported a DAC incidence of 0.4%, while in the series of Bostwick et al this was 0.8%. 13,30 In these two studies it was not noted whether there was an associated acinar adenocarcinoma. Dube et al reported an incidence of 1.3% of pure DAC (55 of 4286 prostate cancers), while an additional 6.3% were combined with acinar adenocarcinoma.…”

“…7,10,33 Papillary architecture is characterised by true fibrovascular stalks, while the cribriform pattern shows back-to-back large glands and intraepithelial bridging, forming slit-like lumens. 7,30,36 In a reproducibility study among international experts, papillary architecture was considered the most helpful feature for diagnosing DAC, followed by cellular features consisting of high-grade nuclear atypia, tall columnar epithelium and elongated nuclei. 37 Cribriform patterns and necrosis were considered more non-specific, while the lack of typical architecture was the most common cause for not assigning a DAC diagnosis.…”

Advanced prostatic ductal carcinoma in a patient with a long survival time following a total pelvis exenteration: A case report

“…Initially, DAP was considered to arise from a Müllerian remnant of the prostatic utricle verumontanum (2). However, subsequent studies have clearly confirmed the prostatic origin of DAP, which is supported by a favorable response to orchiectomy, the expression of prostatic-specific antigen (PSA) and ultrastructural findings (3). DAP is a rare subtype of prostate cancer (PCa) that has a poorly-understood etiology, and more commonly occurs in Caucasian males that are >70 years of age (4).…”